NVIDIA launches Jetson Thor robotics computers for physical AI systems
Investing.com - H.C. Wainwright has reiterated its Buy rating and $100.00 price target on Korro Bio Inc. (NASDAQ:KRRO), following a recent company presentation at the firm’s "H.C. Wainwright @ Home" series. The stock, currently trading at $16.85, has shown remarkable strength with a 21.84% gain over the past week, according to InvestingPro data.
The research firm highlighted Korro Bio’s RNA therapy approach to treating Alpha-1 Antitrypsin Deficiency (AATD), noting it offers high specificity that leverages the body’s machinery to restore normal protein levels and address the disease in both lung and liver.
H.C. Wainwright emphasized that KRRO-110’s intravenous administration provides a potency advantage through instantaneous bioavailability, delivering approximately 95% of the drug directly to cytoplasm in hepatocytes within minutes.
The firm noted Korro Bio aims to achieve steady-state levels of M-AAT protein equivalent to MZ individuals, where typical median total AAT levels stand around 17 (range 11-28) with approximately 70% being M-AAT, compared to ZZ individuals with typical levels of 4-5 total AAT.
Initial Phase 1/2a data for Korro Bio’s treatment is expected sometime this year, with H.C. Wainwright benchmarking the results against competing therapies BEAM-302 and WVE-006. Investors should note that the company’s next earnings report is scheduled for August 6, with analyst price targets ranging from $25 to $180, reflecting diverse views on the company’s potential.
In other recent news, Korro Bio Inc. has been granted orphan drug designation by the European Medicines Agency for its investigational treatment, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD). This designation follows a similar recognition by the U.S. Food and Drug Administration earlier this year. H.C. Wainwright has reiterated a Buy rating for Korro Bio, though it adjusted the company’s 12-month price target from $115.00 to $100.00, citing market dynamics and regulatory challenges in the genetic medicines sector. The firm noted potential regulatory headwinds due to changes in leadership at the FDA’s Center for Biologics and Evaluations Research. Meanwhile, Cantor Fitzgerald initiated coverage on Korro Bio with an Overweight rating and set a price target of $74.00. The firm highlighted the potential impact of KRRO-110 in the competitive field of RNA editing oligonucleotide therapeutics. Cantor Fitzgerald also expressed confidence in Korro Bio’s strategic direction, with anticipation for future clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.